Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia

The present invention relates to cannabigerol (CBG), a cannabinoid, for use in the treatment of chronic insomnia. The present invention moreover relates to Cannabigerol (CBG) , a cannabinoid, for use in the treatment of sleeplessness and "staying in sleep" discomfort orfor use in improving subjective and objective sleep disorders, primary and secondary sleep disorders. In addition, the invention relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid Cannabinodiol (CBND) for use in the treatment of chronic insomnia wherein the ratio of CBG : CBND by weight is between 10:1 and 1:10. In addition, the invention relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid Cannabidiol (CBD) for use in the treatment of insomnia and insomnia related symptoms and depression. In addition, the invention relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid Cannabinodiol (CBND) and cannabinoid tetrahydrocannabinol (THC) for use in the treatment of insomnia, anxiety, anti-depressive, hyperactivity and insomnia related symptoms, preferably wherein the weight ratio of CBG : CBND : THC is between 10-1 : 1-5 : 1-5 or between 1-10 : 5-1 : 5-1.